Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
自体树突状细胞免疫疗法 AGS-003 联合舒尼替尼治疗晚期肾细胞癌 (RCC) 预后不良患者的生存期：II 期研究结果
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1186/s40425-015-0055-3
Amin, Asim; Dudek, Arkadiusz Z; Logan, Theodore F; Lance, Raymond S; Holzbeierlein, Jeffrey M; Knox, Jennifer J; Master, Viraj A; Pal, Sumanta K; Miller, Wilson H Jr; Karsh, Lawrence I; Tcherepanova, Irina Y; DeBenedette, Mark A; Williams, W Lee; Plessinger, Douglas C; Nicolette, Charles A; Figlin, Robert A
肿瘤
肿瘤免疫
树突状细胞
肾癌
细胞生物学
树突状细胞
免疫/内分泌
